The FDA has cleared expanded claims for the Xpert Carba-R, a molecular test for the detection of carbapenemase-producing gram-negative bacteria, from Sunnyvale, Calif.-based Cepheid Inc. The additional claims extend use to the analysis of perirectal swab specimens, allowing test results to guide therapeutic strategies for pure colonies. Read More
